16 However, it may be important to better understand the reasons for the variance between reporting rates by trial sponsors, and to observe the effects of increased enforcement activity by the FDA in recent months
Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinsons disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial
The preservative in bacteriostatic water slows bacterial growth but does not stop it indefinitely, and the peptide itself gradually degrades in solution
Benzyl alcohol can affect the stability of some peptides
Novel Therapeutic Effects in Rat Spinal Cord Injuries: Recovery of the Definitive and Early Spinal Cord Injury by the Administration of Pentadecapeptide BPC 157 Therapy
Terns Pharmaceuticals reports topline 12-week data from its phase 2 trial evaluating oral GLP-1 receptor agonist TERN-601 in obesity